JP2008534520A - ジオクレイン、フロラノール又は類似体ベースの、ホスホジエステラーゼのタイプ１から５のアイソフォーム（ｐｄｅ１、ｐｄｅ２、ｐｄｅ３、ｐｄｅ４、ｐｄｅ５）の強力で選択的な阻害剤としての薬物を開発する方法並びに心血管疾患の研究及び治療のためのそれらの医薬組成物及び関連製品 - Google Patents

ジオクレイン、フロラノール又は類似体ベースの、ホスホジエステラーゼのタイプ１から５のアイソフォーム（ｐｄｅ１、ｐｄｅ２、ｐｄｅ３、ｐｄｅ４、ｐｄｅ５）の強力で選択的な阻害剤としての薬物を開発する方法並びに心血管疾患の研究及び治療のためのそれらの医薬組成物及び関連製品 Download PDF

Info

Publication number
JP2008534520A
JP2008534520A JP2008503326A JP2008503326A JP2008534520A JP 2008534520 A JP2008534520 A JP 2008534520A JP 2008503326 A JP2008503326 A JP 2008503326A JP 2008503326 A JP2008503326 A JP 2008503326A JP 2008534520 A JP2008534520 A JP 2008534520A
Authority
JP
Japan
Prior art keywords
floranol
dioclein
potent
phosphodiesterase
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008503326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534520A5 (cg-RX-API-DMAC10.html
Inventor
レモス、バージニア ソアレス
フランカ コルテス、ステイナー デ
レゼンデ、ブルーノ アルメイダ
ゴンサルベス、ロベルタ リンス
ミラン、ルーベン ダリオ シニステーラ
シュミット、マルティーヌ
リュグニー、クレール
− ジャーク ブルギニョン、ジャン
Original Assignee
ユニベルシダデ フェデラル デ ミナス ジェライス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシダデ フェデラル デ ミナス ジェライス filed Critical ユニベルシダデ フェデラル デ ミナス ジェライス
Publication of JP2008534520A publication Critical patent/JP2008534520A/ja
Publication of JP2008534520A5 publication Critical patent/JP2008534520A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2008503326A 2005-03-31 2006-03-30 ジオクレイン、フロラノール又は類似体ベースの、ホスホジエステラーゼのタイプ１から５のアイソフォーム（ｐｄｅ１、ｐｄｅ２、ｐｄｅ３、ｐｄｅ４、ｐｄｅ５）の強力で選択的な阻害剤としての薬物を開発する方法並びに心血管疾患の研究及び治療のためのそれらの医薬組成物及び関連製品 Pending JP2008534520A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0502411-0A BRPI0502411A (pt) 2005-03-31 2005-03-31 processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
PCT/BR2006/000060 WO2006102728A2 (en) 2005-03-31 2006-03-30 Inclusion compounds of dioclein, floranol or analogs with cyclodextrin and their use for treating cardiovascular diseases

Publications (2)

Publication Number Publication Date
JP2008534520A true JP2008534520A (ja) 2008-08-28
JP2008534520A5 JP2008534520A5 (cg-RX-API-DMAC10.html) 2009-05-14

Family

ID=37053732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503326A Pending JP2008534520A (ja) 2005-03-31 2006-03-30 ジオクレイン、フロラノール又は類似体ベースの、ホスホジエステラーゼのタイプ１から５のアイソフォーム（ｐｄｅ１、ｐｄｅ２、ｐｄｅ３、ｐｄｅ４、ｐｄｅ５）の強力で選択的な阻害剤としての薬物を開発する方法並びに心血管疾患の研究及び治療のためのそれらの医薬組成物及び関連製品

Country Status (5)

Country Link
US (1) US20090270495A1 (cg-RX-API-DMAC10.html)
EP (1) EP1877049A2 (cg-RX-API-DMAC10.html)
JP (1) JP2008534520A (cg-RX-API-DMAC10.html)
BR (1) BRPI0502411A (cg-RX-API-DMAC10.html)
WO (1) WO2006102728A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0800596A2 (pt) * 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
WO2010042633A2 (en) * 2008-10-08 2010-04-15 The General Hospital Corporation Naringenin complexes and methods of use thereof
TW201036624A (en) * 2009-03-27 2010-10-16 Biotropics Malaysia Berhad Aurones as selective PDE inhibitors and their use in neurological conditions and disorders
WO2012101618A1 (en) 2011-01-28 2012-08-02 Barcelcom Têxteis S.A. Compression stockings and tubes with bioactive agents for the treatment of venous insufficiency and varicose veins
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
CN102988279B (zh) * 2011-09-08 2016-06-15 石药集团中奇制药技术（石家庄）有限公司 松属素环糊精超分子包合物及其制备方法
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11217383A (ja) * 1997-10-24 1999-08-10 Pfizer Inc 化合物
WO2004003739A1 (en) * 2002-06-28 2004-01-08 Abb As Revalidation of a compiler for safety control
WO2004002461A2 (en) * 2002-06-26 2004-01-08 Pfizer Limited Combination of pde5 inhibitors with angiotensin ii receptor antagonists
JP2004002282A (ja) * 2001-11-13 2004-01-08 Takeda Chem Ind Ltd 抗癌剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11217383A (ja) * 1997-10-24 1999-08-10 Pfizer Inc 化合物
JP2004002282A (ja) * 2001-11-13 2004-01-08 Takeda Chem Ind Ltd 抗癌剤
WO2004002461A2 (en) * 2002-06-26 2004-01-08 Pfizer Limited Combination of pde5 inhibitors with angiotensin ii receptor antagonists
WO2004003739A1 (en) * 2002-06-28 2004-01-08 Abb As Revalidation of a compiler for safety control

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6012013466; Ｌｉｆｅ　Ｓｃｉ． ７０（１０）, 2002, １１２１-８ *
JPN6012013468; Ｐｌａｎｔａ　Ｍｅｄ． ７０（５）, 2004, ４６５-７ *
JPN6012013470; Ｂｉｏｃｈｅｍ　Ｐｈａｒｍａｃｏｌ． ６８（１０）, 2004, ２０８７-９４ *
JPN6012013472; Ｂｉｏｏｒｇ　Ｍｅｄ　Ｃｈｅｍ　Ｌｅｔｔ． １２（１７）, 2002, ２３１３-６ *
JPN6012013474; Ｊ　Ｐｈａｒｍ　Ｂｉｏｍｅｄ　Ａｎａｌ． ３５（２）, 2004, ３７９-８７ *
JPN6012013476; Ｂｕｌｌ　Ｃｈｅｍ　Ｓｏｃ　Ｊａｐａｎ ６２（８）, 1989, ２４５０-４ *

Also Published As

Publication number Publication date
EP1877049A2 (en) 2008-01-16
BRPI0502411A (pt) 2006-11-28
US20090270495A1 (en) 2009-10-29
WO2006102728A3 (en) 2007-07-26
WO2006102728A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
JP5586487B2 (ja) 治療剤配送のためのシクロデキストリン基材重合体
KR101140110B1 (ko) 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물
JP2016104825A (ja) 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
TW200838560A (en) Cyclodextrin-based polymers for therapeutics delivery
TW201004619A (en) Methods and compositions for therapeutic treatment
EP1420802B1 (en) Increased solubility flavanolignan preparations
KR100198012B1 (ko) 유리율 및 흡수능이 개선된 플라바노리그난 제제, 이 제제의 제조방법 및 이 제제를 함유하는 약학 조성물
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
AU2002323517A1 (en) Increased solubility flavanolignan preparations
US20090270495A1 (en) Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof
CN101955505A (zh) 一种新型免疫抑制剂及其组合物
US20110207685A1 (en) Oral Formulations of Chemotherapeutic Agents
KR102638490B1 (ko) 입자 안정성 및 수용성이 증가된 파이토케미칼 나노입자의 제조방법 및 이의 용도
JP2006506397A (ja) 固体及び半固体高分子イオン・コンジュゲート
JP2008534520A5 (cg-RX-API-DMAC10.html)
Tandel et al. Formulation and Optimization of Rifampicin and Quercetin Laden Liquisolid Compact: In-Vitro and In-Vivo Study
KR101652455B1 (ko) 장기 안정성을 갖는 고함량의 수 가용성 이소플라본 및 그 제조방법
RU2181051C1 (ru) Способ получения инъекционного средства на основе вещества с р-витаминной активностью
US20020072602A1 (en) Micronized mirtazapine
JP2011126791A (ja) アレルギー疾患感受性遺伝子発現抑制物質
KR20160115571A (ko) 알렌드로네이트 결합 금나노입자
CN115135314A (zh) 含有姜黄素类的组合物及其制造方法
WO2007064311A1 (en) Micronized mirtazapine
EP2343056A1 (en) Producing stable adefovir dipivoxil solid dispersions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121109